课题基金 / 基金详情

A Pluripotent Stem Cell Reagent for Corneal Regeneration

A Pluripotent Stem Cell Reagent for Corneal Regeneration
用于角膜再生的多能干细胞试剂
批准号:
8776715
负责人:
JAMES L FUNDERBURGH
金额:
$22.64万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-12-01 至 2016-11-30

项目摘要

项目成果

JAMES L FUNDERBURGH的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):美国每年约有40,000人因角膜混浊而需要角膜移植术,全世界有多达1000万人患有双侧角膜失明。大多数受影响的人没有接受治疗,因为无法获得用于移植的组织。获得供体角膜的困难刺激了对角膜再生替代方法的研究,包括组织生物工程和直接细胞治疗。同种异体组织在移植后具有良好的耐受性,很少发生排斥反应,这促进了细胞治疗的潜力。最近在设备和基于动物模型的细胞治疗方法方面的进展表明,生物工程解决角膜基质和内皮病变的方法大有前途。然而,阻碍细胞技术发展的一个主要障碍是细胞的来源。对于角膜基质和角膜内皮细胞以及成体干细胞的角化细胞,培养扩增的潜力有限,并且细胞的特性因个体供体和制备方法而异,在一致性和质量控制方面提出了挑战。在本项目中,我们将利用人类胚胎干细胞(hESC)研究的两个最新进展,开发一种基于干细胞的角膜工程试剂。我们的实验室已经证明了hESC转化为角膜祖细胞。我们发现角膜祖细胞很容易分化为人角质细胞。同时,其他研究人员描述了一种从hESC中产生几乎无限数量的同质神经嵴细胞的新方法。我们建议将这些技术结合起来,生成一种标准化的hesc衍生干细胞试剂,该试剂具有直接分化为角膜角质细胞和角膜内皮细胞的潜力。该项目将:1)定义从hESC中生成角膜祖细胞的标准操作程序。(2)证明hesc来源的角膜祖细胞的均匀性、稳定性、安全性和低温储存。(3)建立两种基于hESC的荧光报告细胞系,用于评估来源于hESC的角膜角质细胞和内皮细胞的质量和均匀性。(4)利用体外功能测定证明hesc来源的角膜细胞的功能。本项目应用新技术发展来解决角膜细胞再生医学的一个重要障碍。该项目的成功完成将为生物工程和改善角膜失明的细胞治疗方法提供一种定义明确、安全、无限量的细胞试剂。
英文摘要
DESCRIPTION (provided by applicant): About 40,000 individuals annually require keratoplasty for corneal opacity in the USA and up to 10 million people world-wide suffer bilateral corneal blindness. Most affected individuals do not receive treatment because tissue is not available to transplant. Difficulty in obtaining donor corneas has spurred research into alternative approaches to corneal regeneration including bioengineering of tissues and direct cell-based therapy. The potential for cellular based therapy is facilitated by the fact that allogenic tissues are well tolerated and seldom rejected after transplantation. Recent advances in devices and in cell-based therapeutic approaches using animal models show great promise for bioengineering solutions to pathologies of the corneal stroma and endothelium. A major barrier to the advancement of cell-based technologies, however, is a source for cells. In the case of keratocytes of corneal stroma and corneal endothelial cells, as well as of adult stem cells, the potential for expansion in culture is limited, and the properties of the cells vary according to individual donors and preparation methods, presenting a challenge in terms of consistency and quality control. In this project we will develop a stem cell-based reagent for corneal engineering using human embryonic stem cells (hESC), taking advantage of two recent developments in hESC research. Our lab has demonstrated conversion of hESC into corneal progenitor cells. We showed that the corneal progenitor cells readily differentiate to human keratocytes. Simultaneously, other researchers described a new method to produce essentially limitless numbers of homogeneous neural crest cells from hESC. We propose to combine these techniques to generate a standardized hESC-derived stem cell reagent with the potential to differentiate directly into corneal keratocytes and corneal endothelial cells. The project will: 1) Define a standard operating procedure to generate corneal progenitor cells from hESC. (2) Demonstrate homogeneity, stability, safety, and cryo-storage of the hESC-derived corneal progenitor cells. (3) Develop two hESC-based fluorescent reporter cell lines used to assess the quality and homogeneity of the corneal keratocytes and endothelial cells derived from the hESC. (4) Demonstrate functionality of the hESC-derived corneal cells using in vitro functional assays. This project applies novel technical developments to address an important barrier to corneal cell- based regenerative medicine. Successful completion of this project will provide a well-defined, safe, cell-based reagent available in unlimited quantities for use in bioengineering and cytotherapeutic approaches for the amelioration of corneal blindness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioengineering Cornea with Autologous Stem Cells
A Pluripotent Stem Cell Reagent for Corneal Regeneration
Stem Cells for Corneal Engineering
Stem Cells for Corneal Engineering
海外基金